Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009396 | 0.95 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL27675955 | 0.86 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1GAAMAPTCRHBP | |
| SCHEMBL5736978 | 0.84 | KMT2A (0.50) | L3MBTL1ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13150211 | 0.84 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL18698095 | 0.82 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1GAAKMT2AMAPT | |
| SCHEMBL3718147 | 0.81 | FBP1 (0.38) | L3MBTL1ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL5696593 | 0.79 | MAPT (0.43) | ALDH1A1GAAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5737042 | 0.79 | KMT2A (0.48) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1715464 | 0.78 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL30619954 | 0.78 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313041-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157072-A | Novel cyclopento [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022204336-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| CN-106349241-B | Triazole derivative with HSP90 inhibitory activity and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3212631-B1 | PYRAZOLYL-3,4-DIHYDROQUINOLIN-2-ONE ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3212638-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796702-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2012148808-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| EP-1499606-B8 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1673367-A1 | FUSED LACTAM COMPOUNDS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035523-A1 | FUSED LACTAM COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
| EP-1499606-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6713490-B2 | 6-(2-(4-(3-FLUOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-HYDROXY -ETHYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; REDUCED INHIBITORY ACTIVITY AT HERG (HUMAN ETHER-A-GO-GO RELATED GENE) POTASSIUM CHANNEL | PFIZER, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | KAWAMURA MITSUHIRO (JP) | 2003-11-20 | — | — | US | disclosed |
| WO-2003091241-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | GRIN3B, GRIN1, GRIN2A | L3MBTL1 4015/4885ALDH1A1 1251/4885GAA 1733/4885 |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | GRIN2C, GRIN2B, GRIN2A | L3MBTL1 4843/4885ALDH1A1 3460/4885GAA 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.